EVIDENCE LIBRARY
Controlled-Substance Renewal Study Grouped Nonprescribed Opioid and Benzodiazepine Results in One Comparison
A practice review described prescription decisions after urine testing. The reported renewal rates did not demonstrate the clinical safety or appropriateness of those decisions.
A practice review described prescription decisions after urine testing. The reported renewal rates did not demonstrate the clinical safety or appropriateness of those decisions.
The prescribing outcome
Among 474 tests, 214 were classified as inconsistent with the prescribing record. Findings included absent prescribed medicines and positive results for nonprescribed substances.
Renewal was less frequent after inconsistent tests overall. A combined category of nonprescribed opioid or benzodiazepine findings had a higher renewal rate than heroin or cocaine findings.
Keep the grouping intact
The combined renewal percentage was not a benzodiazepine-only estimate. Small numbers in some categories and the practice’s policy context also limited interpretation.
The study did not measure long-term outcomes or prove that a detected substance caused harm. It cannot establish a universal rule for stopping or renewing treatment. A forensic review should retain assay limitations, medication history, the clinician’s actual reasoning, and subsequent care rather than treating a prescribing decision as validation of the screen or proof of safe co-use.
Source paper
Original analysis of the supplied journal article, identified as PMC6820170.